MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

84.89
-0.07
-0.08%
After Hours: 85.33 +0.44 +0.52% 19:59 09/24 EDT
OPEN
84.88
PREV CLOSE
84.96
HIGH
89.48
LOW
84.07
VOLUME
175.19K
TURNOVER
--
52 WEEK HIGH
142.62
52 WEEK LOW
77.60
MARKET CAP
1.41B
P/E (TTM)
-5.8104
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
L1 Capital Pty Ltd Buys Hudbay Minerals Inc, NexGen Energy, Warrior Met Coal Inc, Sells Wells ...
GuruFocus News · 08/23 21:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $170
HC Wainwright & Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $184 to $170.
Benzinga · 08/11 15:23
--HC Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $170 From $184, Maintains Buy Rating
MT Newswires · 08/11 12:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDGL. Analyze the recent business situations of Madrigal Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDGL stock price target is 171.82 with a high estimate of 220.00 and a low estimate of 111.00.
EPS
Institutional Holdings
Institutions: 213
Institutional Holdings: 11.84M
% Owned: 71.30%
Shares Outstanding: 16.60M
TypeInstitutionsShares
Increased
59
926.26K
New
31
394.11K
Decreased
36
2.07M
Sold Out
17
197.16K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Friedman
Chief Financial Officer
Alex Howarth
Corporate Executive/Director
Rebecca Taub
Senior Vice President/General Counsel
Brian Lynch
Senior Vice President
Remy Sukhija
Lead Director/Independent Director
Frederick Craves
Independent Director
Kenneth Bate
Independent Director
James Daly
Independent Director
Keith Gollust
Independent Director
Richard Levy
Independent Director
David Milligan
No Data
  • All
  • Financials
  • Insiders
More
About MDGL
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.